Blood-brain barrier leakage in the penumbra is associated with infarction on follow-up imaging in acute ischemic stroke

Competing Interest Statement

F.L.N., L.S., A.W., M.H., M.P., E.S., M.S., M. Ebinger, R.L., N.N., S.P., J.P., V.T., and B.C. declare no conflicts of interest in relation to this study. L.S. reports fees for congress participation from Angelini Pharma outside the submitted work. M. Endres reports grants from Bayer and fees paid to the Charite from Amgen, Astra-Zeneca, Bayer Healthcare, Boehringer Ingelheim, BMS, Daiichi Sankyo, Sanofi, Pfizer, all outside the submitted work. J.B.F. reports consulting, lecture and advisory board fees from AbbVie, AC Immune, Alzheon, Arte-mida, BioClinica/Clario, Biogen, Bristol Myers Squibb, Brainomix, Cerevast, C2N Diagnostics, Daiichi-Sankyo, EISAI, Eli Lilly, F. Hoffmann-LaRoche AG, Forma Therapeutics, GlaxoSmithKline, Guerbet, Ionis Pharmaceuticals, IQVIA, Janssen, Julius Clinical, jung diagnostics, Lantheus Medical Imaging, Merck, Novo Nordisk, Octapharma AG, Premier Research, ProPharma Group, Prothena Biosciences, Regeneron Pharmaceuticals, Roche, Syneos, Tau Rx, Vertex Pharmaceuticals, and Worldwide Clinical Trials, all outside the submitted work. J.F. reports receiving personal fees from Acandis, Cerenovus, Microvention, Medtronic, Phenox, and Penumbra; receiving grants from Stryker and Route 92; being managing director of eppdata; and owning shares in Tegus and Vastrax; all outside the submitted work. I.G. reports grants from European Union 7th Framework Program during the conduct of the study. C.Z.S. reports speakers fee from Pfizer outside the submitted work. K.W.M. reports consulting and lecture fees from Boehringer Ingelheim, lecture fees from Brainomix and IschemaView, research support from Boehringer Ingelheim all outside the submitted work. G.T. reports consulting or lecture fees from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daichi Sankyo, Portola, and Stryker outside the submitted work.

Clinical Trial

NCT01525290

Funding Statement

The WAKE-UP Trial was supported by a grant (278276) from the European Union Seventh Framework Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Patients or their legal representatives provided written informed consent according to national and local regulations. There was an exception from explicit informed consent in emergency circumstances in some countries. For each study site, the competent authorities and the corresponding ethics committee approved the trial. The trial was registered at http://ClinicalTrials.gov (NCT01525290) and EudraCT (2011-005906-32).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as http://ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes